DIM logo

Sartorius Stedim Biotech S.A. Stock Price

ENXTPA:DIM Community·€16.0b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author

DIM Share Price Performance

€0
-172.85 (-100.00%)
€232.21
Fair Value
€0
-172.85 (-100.00%)
Price €0

DIM Community Narratives

·
Fair Value €232.21 29.4% undervalued intrinsic discount

High Consumable Demand And Regulatory Standards Will Drive Future Success

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
€232.21
29.4% undervalued intrinsic discount
Revenue
10.18% p.a.
Profit Margin
15.02%
Future PE
43.05x
Price in 2029
€287.36

Trending Discussion

No trending discussion available.

Updated Narratives

DIM logo

DIM: Bioprocessing Recovery Signals Will Support Constructive Outlook Despite Higher Sector Risk

Fair Value: €232.21 29.4% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Proven track record with moderate growth potential.

1 Risk
4 Rewards

Sartorius Stedim Biotech S.A. Key Details

€0

Revenue

€0

Cost of Revenue

€0

Gross Profit

€0

Other Expenses

€0

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 22, 2026
2.76
44.71%
8.98%
58.9%
View Full Analysis

About DIM

Founded
1978
Employees
10456
CEO
Rene Faber
WebsiteView website
www.sartorius.com

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.

Recent DIM News & Updates

Narrative Update Jun 26

DIM: Bioprocessing Recovery Signals Will Support Constructive Outlook Despite Higher Sector Risk

The analyst price target for Sartorius Stedim Biotech has been trimmed by €7.93 to €232.21, as analysts factor in slightly higher risk, a modestly lower profit margin outlook, and updated sector views that still identify early signs of recovery in bioprocessing. Analyst Commentary Recent commentary on Sartorius Stedim Biotech reflects a mix of optimism about early recovery signals in bioprocessing and caution about sector risk, which feeds directly into how analysts are thinking about valuation, execution, and growth over the medium term.
Analysis Article Apr 26

Earnings Miss: Sartorius Stedim Biotech S.A. Missed EPS By 7.2% And Analysts Are Revising Their Forecasts

It's been a sad week for Sartorius Stedim Biotech S.A. ( EPA:DIM ), who've watched their investment drop 14% to €162 in...

Recent updates

No updates